BioSpace News Archive

Joining the Company are Giora Davidai, M.D. as Chief Medical Officer, Rhona Shanker as Director of Regulatory Affairs, and Professor Asher Tal, M.D. as Senior Vice President of Clinical Research.

Omeros today announced further positive data from the company’s ongoing Phase II study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Median Technologies, The Imaging Phenomics Company announces the appointment of Dr. Loan Hoang-Sayag as Chief Medical Officer and the appointment of Dr. Fabien Ricard as Medical Director, North America.

Origin has developed a proprietary technology which, for the first time, generates and delivers therapeutic quantities of plasma-generated nitric oxide into the tissue.

The company also intends to submit an application for registration in the European Union (EU) in 2018.

Evolus received confirmation from Health Canada that the NDS for prabotulinumtoxinA, a 900 kilodalton Botulinum toxin Type A, for the treatment of adult patients with glabellar lines, also known as “frown lines” between the eyebrows, has been accepted for review.

Agendia announces new data published today in JAMA Oncology that demonstrate the benefits of the MammaPrint 70-Gene Breast Cancer Risk-of-Recurrence test to significantly change treatment management decisions for patients who had previously received an ‘intermediate’ risk result according to the 21-gene assay.

Oncoquest today announced the signing of a collaborative agreement with TESARO to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab with ZEJULA (niraparib) in the recurrent ovarian cancer setting.

The study found that EndoPredict (EPclin) was superior to the first-generation Oncotype DX Breast Recurrence Score (RS) in predicting breast cancer recurrence in women determined to be at intermediate clinical risk by Nottingham Prognostic Index.

The Company has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock